Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 4/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | GNPAT | O15228 | 2/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.39 |
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.37 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL867577 | 1.00 | FOLH1 (0.51) | FOLH1SLC6A5GNPATCPB2NOD1 | |
| SCHEMBL866580 | 1.00 | FOLH1 (0.51) | FOLH1SLC6A5GNPATCPB2NOD1 | |
| Hydrochloric Acid SCHEMBL1982441 | 0.98 | FOLH1 (0.50) | FOLH1SLC6A5GNPATCPB2NOD1 | |
| Hydrochloric Acid SCHEMBL1982438 | 0.98 | FOLH1 (0.50) | FOLH1SLC6A5GNPATCPB2NOD1 | |
| SCHEMBL45765 | 0.95 | FOLH1 (0.58) | FOLH1SLC6A5GNPATCPB2GSR | |
| SCHEMBL214641 | 0.95 | FOLH1 (0.58) | FOLH1SLC6A5GNPATCPB2GSR | |
| Hydrochloric Acid SCHEMBL2166126 | 0.93 | FOLH1 (0.57) | FOLH1SLC6A5GNPATCPB2GSR | |
| Acetic Acid SCHEMBL268740 | 0.93 | FOLH1 (0.57) | FOLH1SLC6A5GNPATCPB2GSR | |
| Hydrochloric Acid SCHEMBL15914484 | 0.93 | FOLH1 (0.57) | FOLH1SLC6A5GNPATCPB2GSR | |
| SCHEMBL159460 | 0.85 | GNPAT (0.55) | FOLH1SLC6A5GNPATCPB2NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 488 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230309521-A1 | NOVEL METHOD FOR PREPARING ANIMAL MODEL OF CEREBROVASCULAR DISEASE AND METHOD FOR PRODUCING ANIMAL HAVING SMALL INDIVIDUAL DIFFERENCE IN SUSCEPTIBILITY TO CEREBROVASCULAR DISEASE ONSET BY USING ANIMAL MODEL FOR CEREBROVASCULAR DISEASE PREPARED THEREBY | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2023-10-05 | — | — | US | claimed |
| EP-4197323-A1 | NOVEL METHOD FOR PREPARING ANIMAL MODEL OF CEREBROVASCULAR DISEASE AND METHOD FOR PRODUCING ANIMAL HAVING SMALL INDIVIDUAL DIFFERENCE IN SUSCEPTIBILITY TO CEREBROVASCULAR DISEASE ONSET BY USING ANIMAL MODEL FOR CEREBROVASCULAR DISEASE PREPARED THEREBY | Dongguk University Industry-Academic Cooperation Foundation (KR) | 2023-06-21 | — | — | EP | claimed |
| US-20210205468-A1 | SYNTHETIC MULTIDOMAIN PEPTIDE BIOMATERIALS THAT INHIBIT INDUCIBLE NITRIC OXIDE SYNTHASE | WILLIAM MARSH RICE UNIVERSITY (US) | 2021-07-08 | — | — | US | claimed |
| US-20130130263-A1 | GAMETES SEPARATION METHODS, COMPOSITIONS AND USES THEREOF | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 2013-05-23 | — | — | US | claimed |
| EP-2539434-A1 | GAMETES SEPARATION METHODS, COMPOSITIONS AND USES THEREOF | Assistance Publique - Hôpitaux de Paris (FR) | 2013-01-02 | — | — | EP | claimed |
| US-20120076859-A1 | Targeted Lung Delivery of Citrulline and/or Another Nitric Oxide Precursor and a Method for Treatment of Pulmonary Deficiency of Nitric Oxide in Cystic Fibrosis and Other Pulmonary Diseases | ACTIVAERO GMBH (DE) | 2012-03-29 | — | — | US | claimed |
| WO-2011104336-A1 | GAMETES SEPARATION METHODS, COMPOSITIONS AND USES THEREOF | ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (FR) | 2011-09-01 | — | — | WO | claimed |
| EP-2361967-A1 | Gametes separation methods, compositions and uses thereof | Assistance Publique - Hôpitaux de Paris (FR) | 2011-08-31 | — | — | EP | claimed |
| JP-4579349-B2 | — | — | 2010-11-10 | — | — | JP | claimed |
| WO-2005105065-A2 | THIAZOLE-BASED NITRIC OXIDE DONORS FOR TREATING INFLAMMATORY BOWEL DISEASES | RENOPHARM LTD. (IL) | 2005-11-10 | — | — | WO | claimed |
| WO-1996002241-A9 | USE OF NITROGEN OXIDE SPECIES AND ADDUCTS TO INHIBIT SKELETAL MUSCLE CONTRACTION | — | 1996-02-29 | — | — | WO | claimed |
| WO-1996002268-A1 | INHIBITION OF VIRUS BY NITRIC OXIDE | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1996-02-01 | — | — | WO | claimed |
| WO-1996002241-A1 | USE OF NITROGEN OXIDE SPECIES AND ADDUCTS TO INHIBIT SKELETAL MUSCLE CONTRACTION | DUKE UNIVERSITY (US) | 1996-02-01 | — | — | WO | claimed |
| US-5449688-A | Nitric oxide synthase inhibitor or scavenger | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-09-12 | — | — | US | claimed |
| EP-0603335-A4 | ATTENUATION OF THE OPIOID WITHDRAWAL SYNDROME BY INHIBITORS OF NITRIC OXIDE SYNTHASE. | US HEALTH (US) | 1995-07-05 | — | — | EP | claimed |
| WO-1995014465-A2 | METHODS FOR AMELIORATION OF IMMUNODEFICIENCY VIRUS INDUCED NEURODEGENERATION BY COVERING NITRIC OXIDE OR SUPEROXIDE CONCENTRATION | THE JOHNS HOPKINS UNIVERSITY (US) | 1995-06-01 | — | — | WO | claimed |
| WO-1995013805-A1 | USE OF NITRIC OXIDE SYNTHASE INHIBITORS IN THE TREATMENT OF AUTOIMMUNE DISEASES | DUKE UNIVERSITY MEDICAL CENTER (US) | 1995-05-26 | — | — | WO | claimed |
| EP-0603335-A1 | ATTENUATION OF THE OPIOID WITHDRAWAL SYNDROME BY INHIBITORS OF NITRIC OXIDE SYNTHASE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-06-29 | — | — | EP | claimed |
| US-5225440-A | ATTENUATION OF THE OPIOID WITHDRAWAL SYNDROME BY INHIBITORS OF NITRIC OXIDE SYNTHASE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1993-07-06 | — | — | US | claimed |
| WO-1993005775-A1 | ATTENUATION OF THE OPIOID WITHDRAWAL SYNDROME BY INHIBITORS OF NITRIC OXIDE SYNTHASE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1993-04-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205468-A1 | SYNTHETIC MULTIDOMAIN PEPTIDE BIOMATERIALS THAT INHIBIT INDUCIBLE NITRIC OXIDE SYNTHASE | STING1, CGAS, GMPS | FOLH1 1471/4885SLC6A5 4316/4885GNPAT 4260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.